Analyst Bullish on Cogent (COGT) Amid Expected Drug Approval [Yahoo! Finance]
Cogent Biosciences, Inc. (COGT)
Last cogent biosciences, inc. earnings: 11/8 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.cogint.com/investor-relations
Company Research
Source: Yahoo! Finance
Cogent Biosciences Inc. (NASDAQ: COGT ) is one of the 15 stocks with the biggest hedge fund momentum , after gaining 25 hedge fund holders during the fourth quarter of 2025. On February 18, Piper Sandler analysts raised their price target on Cogent Biosciences Inc. (NASDAQ:COGT) t0 $52 from $39. According to these analysts, who maintained an Overweight rating on Cogent Biosciences Inc. (NASDAQ:COGT), their $13 increase on the price target is justified by the company's shift toward regulatory approvals and commercial readiness following fourth-quarter 2025 results. Piper Sandler noted that Cogent Biosciences Inc. (NASDAQ:COGT) submitted a New Drug Application (NDA) for bezuclastinib in non-advanced systemic mastocytosis, with acceptance expected this month. The drug is positioned for potential approval and launch in the second half of 2026. The company also plans to submit an NDA for second-line gastrointestinal stromal tumors in April and an advanced systemic mastocytosis NDA in th
Show less
Read more
Impact Snapshot
Event Time:
COGT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
COGT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
COGT alerts
High impacting Cogent Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
COGT
News
- A Look At Cogent Biosciences (COGT) Valuation After Recent Share Price Volatility [Yahoo! Finance]Yahoo! Finance
- Bezuclastinib SUMMIT Data Reframe Cogent Biosciences Mastocytosis Opportunity [Yahoo! Finance]Yahoo! Finance
- Cogent Biosciences Inc. (COGT) Set for Bezuclastinib Launch, Awaiting FDA Approval [Yahoo! Finance]Yahoo! Finance
- Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual MeetingGlobeNewswire
COGT
Sec Filings
- 2/17/26 - Form SCHEDULE
- 2/17/26 - Form S-8
- 2/17/26 - Form SCHEDULE
- COGT's page on the SEC website